Datum Källa Rubrik Typ Alternativ
2024-06-19 Ziccum Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace mRNA study Pressreleaser Ladda ner | Visa Stäng
2024-06-11 Ziccum Ziccum reports on developments in the portfolio of industry partner projects Pressreleaser Ladda ner | Visa Stäng
2024-06-03 Ziccum Exercise of Employee Stock Options of Series LTI 2021:1 at Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-05-29 Ziccum Kommuniké från årsstämma i Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-05-29 Ziccum Bulletin from the Annual General Meeting of Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 29 May 2024 | Ziccum

Bulletin from the Annual General Meeting of Ziccum AB (publ)

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (the “Company”) on the 29th of May 2024 in Lund.

Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2023 as well as the balance sheet as of 31 December 2023. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2023.

Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2023 and that the results of the Company shall be carried forward.

Board of Directors and auditor
The AGM resolved, in accordance with the Nomination Committee’s proposal, on re-election of Mikaela Bruhammar, Andreas Pettersson Rohman and Per Gerde and election of Jonas Ekblom and Valentina Screpanti Sundquist as board members. Jonas Ekblom was elected as the chairman of the Board of Directors. The AGM elected the audit firm Öhrlings PricewaterhouseCoopers AB as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the Nomination Committee’s proposal. The AGM furthermore resolved in accordance with the Nomination Committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved invoice.

Nomination Committee for the next Annual General Meeting
The AGM resolved, in accordance with the Nomination Committee’s proposal, that the principles for appointing the Nomination Committee adopted at the AGM of 2022 shall apply also for the AGM to be held in 2025.

Resolution on issue authorization
The AGM resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, at one or several occasions and for the period up until the next AGM, resolve to increase the Company’s share capital by issuing new shares, convertibles or warrants. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The number of shares that can be issued, or, in case of issuance of convertibles or warrants, added after conversion or exercise, with the support of authorization shall be limited to 40 percent of the number of outstanding shares at the time of this AGM.

The reason for deviating from the shareholders’ pre-emption rights is to increase the Company’s financial flexibility and the Board of Directors’ scope of action as well as to be able to complete the financing arrangement with Global Corporate Finance, which the Company announced in a press release on 22 January 2024, in a manner favorable to the shareholders. If the Board of Directors decides on an issue deviating from the shareholders’ pre-emption rights, the reason shall be to enable widening of the ownership circle, to acquire or enable the acquisition of working capital (for example by completing the financing arrangement with Global Corporate Finance), to increase the liquidity of the share, to carry out company acquisitions or to acquire or enable the acquisition of capital for company acquisitions.

Incentive program for members of the Board of Directors
The AGM resolved, in accordance with the Nomination Committee’s proposal, to adopt an incentive program for members of the Board of Directors elected at the AGM 2024 consisting of qualified employee stock options. In short, the incentive program includes an issue of not more than 100,000 qualified employee stock options. The AGM furthermore resolved on an issue of not more than 100,000 warrants to ensure delivery of warrants to the participants. Each qualified employee stock option entitles the holder to, free of charge, acquire a warrant entitling the holder to subscribe for one (1) share in the Company during the period from 1 July 2027 up to and including 14 July 2027 at a subscription price corresponding to the quota value of the share.

Incentive program for employees
The AGM resolved, in accordance with the Nomination Committee’s proposal, to adopt an incentive program for certain employees consisting of qualified employee stock options. In short, the incentive program includes an issue of not more than 372,000 qualified employee stock options. The AGM furthermore resolved on an issue of not more than 372,000 warrants to ensure delivery of warrants to the participants. Each qualified employee stock option entitles the holder to, free of charge, acquire a warrant entitling the holder to subscribe for one (1) share in the Company during the period from 1 November 2027 up to and including 14 November 2027 at a subscription price corresponding to the quota value of the share.

Amendment of the Articles of Association
The AGM resolved, in accordance with the Board of Directors’ proposal, to amend the Articles of Association. In addition to editorial changes, amendments were made in order to (i) change the business object to better reflect the object of the Company and (ii) enable the Company to hold digital general meetings following a legislative amendment in the Swedish Companies Act that allows for digital general meetings.

For further information, please contact:
Ann Gidner, CEO, Ziccum AB (publ)
Tel: +46 722 14 01 41
E-mail: gidner@ziccum.com

2024-05-28 Ziccum Ziccum partners with Dagens Industri for Investor Relations program Pressreleaser Ladda ner | Visa Stäng
2024-05-23 Ziccum KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 29 MAJ 2024, KL. 15.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND Pressreleaser Ladda ner | Visa Stäng
2024-05-06 Ziccum Ziccum CEO Analyst video interview: Q1, 2024 highlights Pressreleaser Ladda ner | Visa Stäng
2024-04-30 Ziccum Ziccum AB strengthens patent portfolio with three solid data PCT applications according to expanded IP strategy Pressreleaser Ladda ner | Visa Stäng
2024-04-29 Ziccum Ziccum AB (publ) Interim report Q1 2024 Rapporter Ladda ner | Visa Stäng
2024-04-26 Ziccum Ziccum contracts RFR Solutions for GMP manufacturing in next phase of technology scale-out Pressreleaser Ladda ner | Visa Stäng
2024-04-25 Ziccum KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2024-04-15 Ziccum Ziccum AB (publ) releases Annual Report 2023 Rapporter Ladda ner | Visa Stäng
2024-04-15 Ziccum Ziccum AB (publ) publicerar Årsredovisning 202 Rapporter Ladda ner | Visa Stäng
2024-04-10 Ziccum Ziccum CEO to present at first annual event for Biopharma/Biotech disruptors hosted by major US bank in New York City Pressreleaser Ladda ner | Visa Stäng
2024-04-03 Ziccum Ziccum strengthens and streamlines business and finance functions Pressreleaser Ladda ner | Visa Stäng
2024-03-28 Ziccum Ziccum-presentation och VD-intervju från Kapitalmarknadsdag nu tillgängliga Pressreleaser Ladda ner | Visa Stäng
2024-03-14 Ziccum Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPace Pressreleaser Ladda ner | Visa Stäng
2024-03-01 Ziccum Ziccum reports significant progress in 3D-modelling project with model completion Pressreleaser Ladda ner | Visa Stäng
2024-02-26 Ziccum Ziccum meddelar sista dag för handel med BTU Pressreleaser Ladda ner | Visa Stäng
2024-02-26 Ziccum Ziccum announces last day of trading in BTU Pressreleaser Ladda ner | Visa Stäng
2024-02-16 Ziccum Ziccum offentliggör utfall i företrädesemission Pressreleaser Ladda ner | Visa Stäng
2024-02-16 Ziccum Ziccum announces outcome in rights issue Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Ziccum Ziccums CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Ziccum Ziccums VD Ann Gidner i paneldiskussion om mRNA arrangerat av amerikanska Force Family Office Pressreleaser Ladda ner | Visa Stäng
2024-02-09 Ziccum Sista dag för handel med uniträtter i Ziccum Pressreleaser Ladda ner | Visa Stäng
2024-02-09 Ziccum Last day for trading in unit rights in Ziccum Pressreleaser Ladda ner | Visa Stäng
2024-02-08 Ziccum Ziccums Styrelse och Ledningsgrupp nyttjar samtliga sina Uniträtter i den pågående nyemissionen. Pressreleaser Ladda ner | Visa Stäng
2024-02-08 Ziccum Ziccum's Board of Directors and Management Group use all their Unit Rights in the ongoing new share issue. Pressreleaser Ladda ner | Visa Stäng
2024-02-05 Ziccum Ziccum CEO videointervju: mRNA i fokus Pressreleaser Ladda ner | Visa Stäng
2024-02-05 Ziccum Ziccum CEO video interview: mRNA in focus Pressreleaser Ladda ner | Visa Stäng
2024-02-03 Ziccum Join Ziccum CEO Ann Gidner for ‘Invest Live’, a live digital presentation and Q&A, Tues Feb 6th Pressreleaser Ladda ner | Visa Stäng
2024-02-03 Ziccum Välkommen till 'Invest Live' för att se Ziccums VD Ann Gidner presentera bolaget, som hålls live med efterföljande frågestund, tisdag den 6 februari Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Ziccum Ziccums Q4-rapport – VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2024-01-31 Ziccum Ziccum has proven excellent mRNA activity in animal study with LaminarPace material Pressreleaser Ladda ner | Visa Stäng
2024-01-31 Ziccum Ziccums VD i videointervju med Eucaps Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Ziccum Ziccum launches IR calendar for coming weeks Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Ziccum Ziccum offentliggör informationsmemorandum med anledning av förestående företrädesemission av units Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Ziccum Ziccum publishes Information Memorandum in connection with the forthcoming rights issue of units Pressreleaser Ladda ner | Visa Stäng
2024-01-26 Ziccum ZICCUM AB (publ) Year-End report Q4 2023 Rapporter Ladda ner | Visa Stäng
2024-01-22 Ziccum Ziccum säkrar finansiering till 2025 genom kombinerad riktad emission och företrädesemission för fortsatt genomförande av den ambitiösa affärsplanen. Pressreleaser Ladda ner | Visa Stäng
2024-01-22 Ziccum Ziccum secures financing into 2025 through a combined directed share issue and rights issue to finance the continued execution of its ambitious business plan Pressreleaser Ladda ner | Visa Stäng
2024-01-10 Ziccum Ziccum reports successful mRNA/LNP Feasibility Study with major Biotech Corporation Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Ziccum CEO's Seasons Greetings 2023: A pivotal year of significant results Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Ziccum VDs Julhälsning 2023: Ett avgörande år med betydande resultat Pressreleaser Ladda ner | Visa Stäng
2023-12-04 Ziccum Ziccum signs Academic Collaboration with University of Copenhagen on inhalable mRNA vaccine project Pressreleaser Ladda ner | Visa Stäng
2023-12-01 Ziccum Ziccum to present at ‘Inhaled Biologics’ live webinar with KOL Assoc Prof. Per Gerde Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Ziccum Ziccum AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-28 Ziccum Feasibility studies and continued revenue generation after third agreement signed with leading industry player: CEO Interview Pressreleaser Ladda ner | Visa Stäng
2023-11-27 Ziccum Ziccum AB: BioStock: Ziccum har säkrat avtal inom alla tre marknadssegment Pressreleaser Visa Stäng
2023-11-09 Ziccum Ziccum launches News portal Pressreleaser Ladda ner | Visa Stäng
2023-11-08 Ziccum Ziccum CEO Analyst video interview: new industry Agreement, Q3 highlights Pressreleaser Ladda ner | Visa Stäng
2023-11-07 Ziccum Ziccum signs agreement for Vaccine Evaluation project with major US Biomanufacturing corporation Pressreleaser Ladda ner | Visa Stäng
2023-10-27 Ziccum Ziccums Q3-rapport – VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-10-25 Ziccum ZICCUM AB (publ) Interim report Q3 2023 Rapporter Ladda ner | Visa Stäng
2023-10-23 Ziccum Ziccum reports positive results from external validation of mRNA activity after LaminarPace treatment Pressreleaser Ladda ner | Visa Stäng
2023-10-18 Ziccum Ziccum AB: Ziccum presenterar på BioStock Life Science Summit den 25 oktober Pressreleaser Visa Stäng
2023-09-05 Ziccum Ziccum appoints senior biotech manager as new COO Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Ziccum Ziccum CEO Analyst interview part 2 Pressreleaser Ladda ner | Visa Stäng
2023-08-25 Ziccum Analyst interview with Ziccum CEO on significant milestones achieved Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Ziccum Ziccum to present at Investor Conference BioFuture 2023 in New York Pressreleaser Ladda ner | Visa Stäng
2023-07-24 Ziccum Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Ziccum Ziccums Q2-rapport - VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Ziccum ZICCUM AB (publ) Interim report Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-17 Ziccum Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

29 Jan 2025 | Bokslutskommuniké 2024